The World Anti-Doping Agency maintains the global standard for prohibited substances in competitive sport. The 2026 Prohibited List, effective January 1, 2026, includes specific language around peptides that every competitive athlete, coach, and sports medicine professional should understand. Ignorance of the list is not a defense against sanctions. Athletes are solely responsible for everything they put in their bodies, including all supplements, medications, and research chemicals.
This article provides the complete list of peptide substances banned in 2026 and beyond, the rationale behind their prohibition, detection methods, and practical guidance for athletes who want to compete clean.
The regulatory framework: S2.2 of the 2026 Prohibited List
Section S2.2 covers peptide hormones, growth factors, related substances, and mimetics. This section explicitly prohibits:
- Growth hormone and its releasing factors: GHRH analogs including CJC-1295, sermorelin, and tesamorelin; GHRPs including ipamorelin, GHRP-2, GHRP-6, and hexarelin; and all GH secretagogues.
- Growth factors: IGF-1 and its analogs, mechano growth factor, platelet-derived growth factor, vascular endothelial growth factor, and fibroblast growth factors.
- Peptide hormones: Erythropoietin, hCG, LH, ACTH, and their releasing factors.
- Thymosin beta-4 and other thymosin peptides including TB-500.
- BPC-157 and related pentadecapeptides.
- Any other growth factor or peptide hormone affecting muscle, tendon, or ligament protein synthesis, vascularization, energy utilization, regenerative capacity, or fiber type switching.
Why these peptides are banned
WADA prohibits substances that meet at least two of three criteria: performance enhancement potential, actual or potential health risk, and violation of the spirit of sport. The banned peptides meet all three.
GH-releasing peptides directly increase growth hormone and IGF-1, which enhance recovery, reduce body fat, and increase lean mass. Growth factors like TB-500 and BPC-157 accelerate tissue repair beyond natural healing capacity. EPO increases oxygen-carrying capacity. These effects confer an unfair competitive advantage that cannot be achieved through training alone.
The health risks are also real. Unsupervised GH and IGF-1 elevation increases cancer risk, causes insulin resistance, and can lead to acromegaly-like changes in soft tissues. EPO thickens the blood and increases stroke and myocardial infarction risk. Peptides from unregulated sources carry additional risks of contamination and infection.
Detection and testing methods
WADA-accredited laboratories use mass spectrometry-based methods to detect peptide doping. The technology has improved significantly in recent years, with several important considerations for athletes.
- Detection windows: Short-acting peptides like GHRPs may clear within hours. Longer-acting compounds like CJC-1295 with DAC may be detectable for days to weeks.
- Metabolite detection: Some labs target peptide metabolites rather than parent compounds, extending detection windows beyond the half-life of the original substance.
- Biomarker testing: The GH-2000 and IGF-1 tests detect unnatural growth hormone and IGF-1 patterns even when the peptide itself has cleared from circulation.
- Stability: Peptides degrade rapidly in urine at room temperature. Some testing now uses dried blood spots for better sample stability and easier transport.
- Long-term storage: Samples from major competitions are stored for up to ten years and can be retested as detection methods improve.
Therapeutic Use Exemptions
A Therapeutic Use Exemption allows an athlete to use a prohibited substance for a legitimate medical condition. TUEs for peptide hormones are possible but rarely granted for performance-enhancing indications. The standard is high: the athlete must demonstrate that no permitted alternative exists and that the condition was not caused by prior misuse of prohibited substances.
- Insulin: TUEs are commonly granted for type 1 diabetes with proper documentation.
- hCG: May be granted for male hypogonadism with documented pituitary or testicular pathology confirmed by endocrinologist evaluation.
- Growth hormone: Extremely rare; requires documented growth hormone deficiency with formal stimulation testing and specialist confirmation.
- BPC-157, TB-500, CJC-1295, ipamorelin: No established medical indication exists that would support a TUE for these compounds.
What the rules actually say
For competitive athletes in WADA-governed sports, the safest and only compliant approach is complete avoidance of all peptides listed in S2.2 and S0. This is not negotiable. The strict liability principle means athletes are responsible for any prohibited substance found in their system regardless of intent, source, or knowledge.
Practical steps include avoiding research chemical websites entirely, checking all supplements for peptide contamination, being cautious with compounded medications and verifying every ingredient, understanding that natural or endogenous status does not mean permitted, and consulting with a sports medicine physician before beginning any peptide or hormone therapy. When in doubt, do not take it. The risk of a multi-year competition ban far outweighs any theoretical benefit from an unproven peptide.